Nido Biosciences is a clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics to treat various neurodegenerative disorders. The company’s lead program in Spinal Bulbar Muscular Atrophy (SBMA) is in the clinic and is poised to be the first disease-modifying therapy for the indication.